Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population.

Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population. Abstract Text:

    l ramiL Rami,j l molinuevoJ L Molinuevo,r sanchez-valleR Sanchez-Valle,b boschB Bosch,a villarA Villar,l ramiL Rami,j l molinuevoJ L Molinuevo,r sanchez-valleR Sanchez-Valle,b boschB Bosch,a villarA Villar,

    OBJECTIVES: To design and validate a new screening test for amnestic Mild Cognitive Impairment (A-MCI) and early stage Alzheimer's disease (AD). METHODS: We develop a verbal episodic and semantic memory test: the Memory Alteration Test (M@T). Discriminative validity was assessed in a population sample of 400 aged individuals from primary care population centres in Barcelona, Spain, 50 patients with A-MCI according to Petersen et al. criteria, and 66 with early AD (Global Deterioration Scale-4 stage) according to the NINCDS-ADRDA criteria. RESULTS: The M@T is quick, 5-min, and easy to administer and to score. M@T mean scores were significantly different between all groups: 41.4 (SD = 4.9) in the primary care population, 31.5 (SD = 3.9) in the A-MCI group and 21.8 (SD = 4.9) in early AD. A cut-off score of 37 points had a sensitivity of 96% and a specificity of 79% for A-MCI diagnosis (AUC = 0.932). A cut-off score of 28 points had a sensitivity of 92% and a specificity of 98% for early AD diagnosis (AUC = 0.99) and a sensitivity of 87 % and specificity of 82% to differentiate between A-MCI and AD patients. CONCLUSION: The M@T provides efficient and valid screening for A-MCI and early stage AD, and discriminates between A-MCI and early AD patients.

    Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population. Publishing Authors By Initials

    l ramiL Rami,jl molinuevoJL Molinuevo,r sanchez-valleR Sanchez-Valle,b boschB Bosch,a villarA Villar,l ramiL Rami,jl molinuevoJL Molinuevo,r sanchez-valleR Sanchez-Valle,b boschB Bosch,a villarA Villar,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population. Journal Published:

    PUBLICATION TYPE: Research Support, Non-U.S. Gov

    Journal: International journal of geriatric psychiatry

    VOLUME: 22

    Page Numbers: 294-304

    Journal Abbreviation:

    ISSN: 0885-6230

    DAY: 28

    MONTH: Apr

    YEAR: 2007

    Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 8710629

    Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T (Memory Alteration Test) in the primary care population.

    AFFILIATION: Memory-Alzheimer Unit, Department of Neurology, Institute of Neurosciences, Hospital Clinic i Universitari de Barcelona, Institut d'Investigaciň Biomédica August Pi I Sunyer, Spain. jlmoli@clinic.ub.es

    Country: England

    England Research PublicationEngland Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Int J Geriatr Psychiatry

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Screening for amnestic mild cognitive impairment and early Alzheimer's disease with M@T Memory Alteration Test in the primary care population Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News